SYNTHORX
Dead / Abandoned — Abandoned — no statement of use filed (as of 16 May 2022)
What this means for you
This application is over — abandoned 16 May 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88083193
- Mark type
- Stylized text
- Filed
- 17 Aug 2018
- Published for opposition
- 12 Feb 2019
- Abandoned
- 16 May 2022
- Attorney of record
- Karen Lim
Goods and services
- Class 005 — Pharmaceuticals: Protein therapeutics expressed, prepared or manufactured using a semi-synthetic organism, namely, pharmaceutical preparations for use in immunology, oncology including immuno-oncology, cardiovascular and metabolic diseases, and infectious diseases; protein therapeutics expressed, prepared or manufactured using a semi-synthetic organism, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, including cancer, autoimmune and inflammatory diseases including transplantation and delayed-type hypersensitivity, respiratory diseases, gastrointestinal diseases, cardiovascular and metabolic diseases, pathogen infections, musculoskeletal diseases, ophthalmologic and dermatologic diseases, genitourinary diseases, degenerative diseases, and orphan diseases; protein therapeutics namely, pharmaceutical preparations for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, and geriatrics; protein therapeutics, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, including cancer and autoimmune disorders, cytokines, interferons, tumor cell targeting and cytolytic agents, tolerogenic and antiallergic factors, growth and differentiation factors, hormones, replacement enzymes, coagulation factors, lipid binding proteins, protein factors for manufacturing of adoptive cell therapy products, anti-infectives, pain killers, and tissue repair factors; non-natural protein modifications for use in connection with a variety of therapeutic areas, namely, protein arrays for medical diagnosis purposes; pharmaceutical preparations, namely, synthetic proteins for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, and geriatrics
- Class 042 — Scientific and technological services: Medical research; scientific research in the field of DNA; pharmaceutical research and development; laboratory research services in the field of pharmaceuticals; pharmaceutical research in the field of protein therapeutics; pharmaceutical research in the fields of immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, geriatrics, genetics and phenomics, pathology and forensics, proteomics, and veterinary medicine and diagnostics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical research using a semi-synthetic organism for use in drug development; pharmaceutical research, namely, research relating to synthetic proteins incorporating one or more non-natural amino acids for improving pharmacological properties; pharmaceutical research, namely, research relating to synthetic proteins for use in connection with a wide variety of therapeutic agents
Owner
- Synthorx, Inc., La Jolla, CA, US
- Synthorx, Inc., La Jolla, CA, US
Prosecution history
- 16 May 2022 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 16 May 2022 — ABANDONMENT - NO USE STATEMENT FILED
- 25 Aug 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Aug 2021 — SOU EXTENSION 5 GRANTED
- 19 Aug 2021 — SOU EXTENSION 5 FILED
- 24 Aug 2021 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 19 Aug 2021 — SOU TEAS EXTENSION RECEIVED
- 16 Feb 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Feb 2021 — SOU EXTENSION 4 GRANTED
- 12 Feb 2021 — SOU EXTENSION 4 FILED
- 12 Feb 2021 — SOU TEAS EXTENSION RECEIVED
- 11 Sept 2020 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Sept 2020 — SOU EXTENSION 3 GRANTED
- 09 Sept 2020 — SOU EXTENSION 3 FILED
- 09 Sept 2020 — SOU TEAS EXTENSION RECEIVED